ELAVL2 and lung disorder: These included the activation of co-inhibitory and co-stimulatory immune checkpoints, revealed as Hub genes, in the pulmonary disease, which may have an impact on activation of CD8+ and CD4+ T cells and other T-cell related-pathways.